Artificial Organs Market Size, Share & Trends Analysis Report By Technology (Mechanical bionics, Electronic bionics), By Product (Kidney, Heart, Lungs, Liver, Pancreas, Artificial Organs, Artificial Bionics, Cochlear implant, Exoskeleton, Bionic limbs, Vision bionics, Brain bionics), By Type (Artificial Heart, Prosthetic heart valves, Ventricular assistance devices, Cardiac pacemakers, Material Type, Silicon, Plastics, Steel), By Organ Type (Permanent Artificial Organs, Temporary Artificial Organs) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Artificial Organs Market Size & Trends

The global artificial organs market size was valued at USD 20.6 billion in 2023 and is projected to reach from USD 22.2 billion to USD 40.6 billion by 2032, registering a CAGR of 7.83% during the forecast period (2024-2032).

The increase in artificial organs market share during the forecast period is related to increasing incidence of organ failure and technological advancements.

An artificial organ refers to a human-made device or tissue implanted or integrated into a human body to replace, replicate, or augment the functions of a natural organ. These devices are designed to interface with living tissue, allowing patients to regain normal physiological functions and improve their quality of life. While artificial organs are not necessarily linked to life-support functions, they often play a crucial role in sustaining life, especially in cases where natural organs fail. Examples of artificial organs include artificial limbs, prosthetic heart valves, ventricular assist devices, cardiac pacemakers, artificial kidneys, and more.

The market for artificial organs is gaining momentum due to the increasing demand for organ transplants, driven by a rise in organ failure cases resulting from chronic diseases, accidents, and lifestyle changes. According to the American Transplant Foundation, approximately 114,000 individuals in the U.S. are currently on the waiting list for organ transplants. Unfortunately, about 20 people lose their lives each day while waiting for a suitable donor organ, highlighting the critical need for artificial organs to bridge this gap. This demand is further exacerbated by the growing prevalence of conditions such as cardiovascular diseases, chronic kidney diseases, and pulmonary fibrosis, which contribute significantly to organ failure.

Highlights

• Artificial organs hold a significant share by product.
• Electronic Bionics dominates the market by technology.
• Permanent Artificial Organs are widely used by organ type.

Artificial Organs Market Growth Factors

Increasing incidence of organ failure

The rising prevalence of organ failure is a significant driver of the artificial organs market. Factors such as severe sepsis, cardiovascular diseases, trauma, and chronic conditions like heart diseases and chronic kidney diseases are contributing to the growing demand for organ transplant procedures. According to the World Health Organization (WHO), the global incidence of sepsis is estimated to affect nearly 49 million people annually, with a substantial number of these cases leading to organ dysfunction. The American Transplant Foundation reports that over 114,000 people are currently on the organ transplant waiting list in the U.S., emphasizing the urgent need for artificial organs to address the scarcity of viable donor organs.

Technological advancements in artificial organs

The increasing utilization of sophisticated biomaterials and advancements in technology, such as 3D bioprinting and artificial intelligence (AI), are driving the expansion of the artificial organs market. These technologies have enabled the development of artificial organs that closely replicate the functions of natural organs, thereby improving patient outcomes and offering critical life support. For instance, 3D bioprinting allows for the layer-by-layer fabrication of complex organ structures using biocompatible materials, which can be tailored to individual patient needs. Additionally, AI-driven organ-on-a-chip (OOC) systems are being developed to simulate tissues' biomechanics and physiological responses, enabling in vitro studies of disease mechanisms and drug efficacy.

Artificial Organs Market Restraining Factors

Lack of skilled professionals

A significant challenge hindering the growth of the artificial organs market is the need for more skilled professionals capable of designing, manufacturing, and implanting these complex devices. The development and implantation of artificial organs require highly specialized expertise in biomedical engineering, materials science, and clinical medicine. Moreover, the high cost of cultivating and transplanting artificial organs limits their accessibility to a broader population. For example, the average price of a heart transplant in the U.S. exceeds USD 1.6 million, which can be prohibitive for many patients, even with insurance coverage.

Technological penetration in developing countries

Inadequate technology penetration in developing nations is another significant restraint for the artificial organs market. Many low- and middle-income countries (LMICs) need more infrastructure and resources to adopt advanced medical technologies, including artificial organs. Additionally, the high cost of these devices, coupled with limited healthcare funding, further restricts their availability in these regions. As a result, patients in LMICs often face prolonged waiting times for transplants or are unable to access artificial organs altogether.

Artificial Organs Market Opportunities

Rising demand for organ transplants

The growing demand for organ transplants presents a substantial opportunity for the artificial organs market. The global organ shortage crisis is a well-documented issue, with many patients succumbing to their conditions while waiting for donor organs. In India alone, over three lakh patients are on the waiting list for organ transplants, with an average of 20 individuals dying each day due to a lack of available organs. The situation is similar in other parts of the world, where the gap between organ supply and demand widens. The development and adoption of artificial organs offer a viable solution to this crisis by providing life-saving alternatives for patients who would otherwise not survive the wait for a donor organ.

Innovative product development

The artificial organs market is poised for significant growth through the development of innovative products. Advances in technology, such as 3D bioprinting and organ-on-a-chip platforms, enable the creation of more sophisticated and personalized artificial organs. For example, using microfluidic systems in organ-on-a-chip platforms allows for the precise replication of organ functions in vitro, facilitating the testing of new drugs and the study of disease mechanisms. Additionally, 3D bioprinting technology enables the production of complex organ structures with multiple cell types and bioactive agents, which can be integrated into the human body to restore or enhance organ function. These innovations are expected to drive the artificial organs market forward by improving patient outcomes and expanding the range of available treatment options.

Artificial Organs Market Regional Analysis

The global artificial organs market share is bifurcated into North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North america : dominant region with 37% growth rate (cagr)

North America dominates the global artificial organs market, accounting for a market share of approximately 37% in 2023. The region's leadership is attributed to the availability of advanced medical infrastructure, a high incidence and prevalence of chronic diseases, and continuous technological advancements in healthcare. The United States, in particular, is a significant market, with an estimated value of USD 6.65 billion in 2023, projected to surpass USD 15.75 billion by 2030. The growing demand for organ transplants, driven by the increasing burden of chronic diseases and the aging population, is a crucial factor contributing to artificial organs market growth in North America. Additionally, the presence of leading market players, ongoing research and development (R&D) activities, and favorable government initiatives further bolster the region's market position.

Europe : rapid growth in germany, france & uk

Europe is the second-largest market for artificial organs, with a share of 33% in 2023. The market in this region is driven by factors such as the rising prevalence of chronic diseases, an aging population, and increasing awareness of organ transplantation. Countries like Germany, France, and the United Kingdom are at the forefront of the European market, with robust healthcare systems and strong government support for organ donation and transplantation programs. The European artificial organ market is also benefiting from advancements in biomaterials, tissue engineering, and 3D bioprinting, which drive innovation and expand the range of available treatment options.

The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, with a CAGR of 13.8%. This growth is driven by the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing awareness of organ transplantation in emerging economies such as China, India, and Japan. The region's large population base, coupled with the rising burden of chronic diseases such as diabetes and cardiovascular conditions, is creating a significant demand for artificial organs. Additionally, the expanding middle-class population, improving healthcare infrastructure, and increasing government initiatives to promote organ donation contribute to Asia-Pacific artificial organs market growth.

Latin America represents a smaller but rapidly growing market for artificial organs, with Brazil, Mexico, and Argentina being the key contributors. The region is experiencing an increasing incidence of chronic diseases, particularly cardiovascular diseases and diabetes, which is driving the demand for organ transplants and artificial organs. Additionally, growing awareness of organ donation, improving healthcare infrastructure, and government initiatives to promote transplantation are expected to boost market growth in Latin America.

Artificial Organs Market Segmental Analysis

The global artificial organs market is segmented based on product, technology, type, and organ type.

By product

The market is further segmented by product into artificial organs, kidneys, heart, lungs, liver, pancreas, artificial bionics, cochlear implants, exoskeleton, bionic limbs, vision bionics, and brain bionics.

The artificial kidneys segment accounted for a significant market share in 2023. The high incidence of kidney failure, driven by factors such as chronic kidney disease (CKD), diabetes, hypertension, and prolonged use of nephrotoxic drugs, has led to a growing demand for artificial kidneys. According to the National Kidney Foundation, CKD affects approximately 10% of the global population, and the number of patients requiring dialysis or kidney transplants is expected to increase by 60% over the next decade. This trend underscores the critical need for artificial kidneys to address the rising burden of kidney disease.

The artificial liver segment is expected to experience substantial growth in the coming years, driven by the rising prevalence of liver diseases, mainly due to alcohol consumption and non-alcoholic fatty liver disease (NAFLD). The World Health Organization (WHO) reports that liver cirrhosis and other chronic liver diseases are among the top 10 causes of death worldwide, with alcohol-related liver disease being a significant contributor. The growing demand for artificial livers is further supported by advancements in bioartificial liver technology, which aim to provide temporary liver support to patients awaiting transplants or recovering from acute liver failure.

By technology

The market is further segmented by technology into mechanical bionics and electronic bionics.

Mechanical bionics represents the traditional market segment, focusing on developing devices such as prosthetic limbs, exoskeletons, and ventricular assist devices (VADs). The increasing prevalence of disabilities and advancements in materials science and biomechanics have led to the development of more sophisticated and functional prosthetic devices. For example, the introduction of lightweight, durable materials such as carbon fiber composites has revolutionized the design of prosthetic limbs, enabling patients to achieve greater mobility and independence.

Electronic bionics is an emerging segment that leverages advanced electronics and AI to create devices that can interface directly with the nervous system or other biological processes. This segment includes products such as cochlear implants, bionic eyes, and brain-computer interfaces (BCIs). The growing interest in electronic bionics is driven by the potential to restore lost sensory functions, enhance human capabilities, and improve the quality of life for individuals with severe disabilities. For instance, recent developments in BCIs have enabled patients with paralysis to control robotic limbs or computer interfaces using their thoughts, representing a significant neuroprosthetic breakthrough.

By type

The market is further segmented by type into artificial hearts, prosthetic heart valves, Vehicular assistance devices, cardiac pacemakers, material type, silicon, plastics, and steel.

An artificial heart is a mechanical apparatus comprising a ventricle and all four cardiac valves, which assume the role and operation of the natural heart. An electrical cable called a driveline is connected to an external power source after being implanted within the body in place of the native heart. It reinstates the regular circulation of blood to the remaining bodily organs. Patients who lose both ventricles before receiving a heart transplant are candidates for an artificial heart.

Prosthetic heart valves are apparatuses implanted instead of ailing or damaged heart valves. Biological or mechanical, these prosthetic valves are vital for restoring normal heart function. They comprise mechanical circulatory support devices, including pacemakers and artificial cardiac valves.

Ventricular Assist Devices (VADs) are mechanical pumps designed to assist individuals with weakened hearts maintain cardiac function and blood flow. Both the left ventricle (LVAD) and right ventricle (RVAD) may be supported by them (BiVAD). LVADs are a form of artificial heart pump that supplies oxygen-enriched blood to other organs via the aorta by assuming the function of the left ventricle.

By organ type

The market is further segmented by organ type into Permanent Artificial Organs and Temporary Artificial Organs.

Permanent Artificial Organs are bioartificial organs capable of replacing and curing failed organs entirely and perpetually. They comprise biodegradable polymers and living cells and can regenerate failed or defective organs. Illustrative instances of permanent artificial organs encompass the complete artificial heart, an implanted device to substitute the endogenous heart. It is powered externally via a driveline and an electrical cable. Total artificial hearts (TAI) reinstate regular blood circulation to other bodily organs. They are considered for patients whose ventricles fail before that of a heart transplant.

Temporary artificial organs consist of inanimate metals and polymers (plastics) to simulate biological or mechanical organ function. They can only temporarily and partially replace and repair malfunctioning organs in the human body. Temporary artificial organs encompass mechanical machines known as ventricular assist devices (VADs), which support individuals with compromised cardiac function and blood circulation. Both the left ventricle (LVAD) and right ventricle (RVAD) may be supported by them (BiVAD). LVADs are a form of artificial heart pump that supplies oxygen-enriched blood to other organs via the aorta by assuming the function of the left ventricle.

Recent Developments

• April 2024- Medtronic announced the launch of the new Symplicity Spyral renal denervation system in Europe after receiving CE Mark approval. This device is intended for the treatment of hypertension, marking a significant step in the development of advanced artificial organs targeting chronic conditions.
• March 2024- Abbott introduced the latest version of its CentriMag Acute Circulatory Support System, featuring enhanced patient monitoring capabilities and improved biocompatibility. This system is designed to support patients with acute heart failure, offering temporary circulatory support.